There are two available single-dose vaccines—one developed by Pfizer (called Abrysvo) and the other developed by GSK (called Arexvy). Both vaccines were determined to be equally effective by the CDC Advisory Committee on Immunization Practices (ACIP). In 2023, CDC recommended that adults age 60 and over consult with their health care providers about receipt of the RSV vaccine. 

On June 26, 2024, the CDC issued updated guidance for these vaccines in people who are 60 and older. The updated guidance is that: 

  • People 75 years of age and older who did not receive an RSV vaccine in 2023 should get one dose of the RSV vaccine in late summer or early fall. 
  • People 60-74 who did not receive an RSV vaccine in 2023 and who have certain chronic medical conditions or live in nursing homes should receive one dose of the RSV vaccine for the upcoming respiratory virus season. 
  • People who received an RSV vaccine in 2023 do not need to get a second dose this season. The RSV vaccine is not currently an annual vaccine.

Updated June 28, 2024